- Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial-based Neurodegenerative Conditions
- Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
- Sana Biotechnology to Present at May and June 2024 Investor Conferences
- Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
- Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
- Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Sana Biotechnology Announces Pricing of Upsized Public Offering
- Sana Biotechnology Announces Proposed Public Offering of Common Stock
- Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
More ▼
Key statistics
On Friday, Sana Biotechnology Inc (SANA:NSQ) closed at 6.40, 133.15% above the 52 week low of 2.75 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.25 |
---|---|
High | 6.61 |
Low | 6.15 |
Bid | 6.27 |
Offer | 6.70 |
Previous close | 6.05 |
Average volume | 2.16m |
---|---|
Shares outstanding | 221.50m |
Free float | 202.38m |
P/E (TTM) | -- |
Market cap | 1.42bn USD |
EPS (TTM) | -1.53 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 21:00 BST.
More ▼